

Portugal

Population 2016

10 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.21 (0.21–0.22)	2 (2–2.1)
Mortality (HIV+TB only)	0.045 (0.029–0.064)	0.43 (0.28–0.62)
Incidence (includes HIV+TB)	2.1 (1.8–2.4)	20 (17–23)
Incidence (HIV+TB only)	0.29 (0.24–0.34)	2.8 (2.4–3.3)
Incidence (MDR/RR-TB)**	0.028 (0.017–0.04)	0.27 (0.16–0.39)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.089 (0.075–0.1)	0.64 (0.54–0.74)	0.73 (0.62–0.84)
Males	0.099 (0.084–0.11)	1.2 (1–1.4)	1.3 (1.1–1.5)
Total	0.19 (0.16–0.22)	1.9 (1.6–2.2)	2.1 (1.8–2.4)

TB case notifications, 2016

Total cases notified	1 836
Total new and relapse	1 794
- % tested with rapid diagnostics at time of diagnosis	16%
- % with known HIV status	66%
- % pulmonary	72%
- % bacteriologically confirmed among pulmonary	87%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.13 (0.11–0.15)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	168	14%
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			19 (10–27)
Estimated % of TB cases with MDR/RR-TB	0.98% (0.51–1.7)	6.9% (2.8–14)	
% notified tested for rifampicin resistance	44%	52%	811
MDR/RR-TB cases tested for resistance to second-line drugs			5
Laboratory-confirmed cases		MDR/RR-TB: 15, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 16, XDR-TB: 2	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	72%	2 114
Previously treated cases, excluding relapse, registered in 2015	56%	39
HIV-positive TB cases registered in 2015	51%	218
MDR/RR-TB cases started on second-line treatment in 2014	52%	25
XDR-TB cases started on second-line treatment in 2014	67%	3

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017

National TB budget (US\$ millions)

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically